Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson announces Prezista licensing agreement

Johnson and Johnson announces Prezista licensing agreement

10th April 2007

Johnson & Johnson company Tibotec Pharmaceuticals has announced that it has signed a non-exclusive licensing agreement with South African firm Aspen regarding the registration, packaging and distribution of Prezista (darunavir) in sub-Saharan Africa.

Tibotec reports that it has chosen Aspen for this position because of the company’s existing distribution network in Africa and its previous experience in broadening the access to Aids treatment in areas where resources are limited.

Prezista is to be used by treatment-experienced HIV patients with a focus on those that have failed an existing protease-inhibitor regimen, with the compound to be co-administered with ritonavir and other antiretrovirals.

Julie McHugh, company group chairman of virology at Tibotec, said: “More and more patients in sub-Saharan Africa are in need of access to new therapies when their existing regimens fail.”

She added that the firm was happy to work with a local firm to speed up the registration of the compound in Africa and to develop sustainable supply chains that are capable of meeting the patient need in the area.

In February 2007, Tibotec announced that Prezista received conditional marketing authorisation in the European Union as a treatment for patients infected with HIV-1.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.